CNBC Utilities Page Drugs

More

  • Sarepta soars as FDA delays review of key drug

    CNBC's Dominic Chu reports on Sarepta Therapeutics and its Duchenne muscular dystrophy drug trial. The "FMHR" traders weigh in on the trade.

  • SAN FRANCISCO, May 20- A San Francisco- based company has won a U.S. government-sponsored competition with an alcohol monitoring devices that can be worn on the wrist, the latest milestone in the development of wearable technologies that monitor and diagnose medical conditions. BACtrack, a privately held medical device maker, took the $200,000 top prize in the...

  • Obama: Congress needs to pass Zika bill soon

    President Obama speaks about the U.S. response to the Zika virus after a briefing from the CDC.

  • Obama: Plans in place to develop Zika diagnostics

    President Obama speaks about the U.S. response to the Zika virus after a briefing from the CDC.

  • Obama: US Zika cases appear to be travel-related

    CNBC's Eamon Javers reports on President Obama's comments after a briefing on the Zika virus.

  • Sarepta awaits drug approval

    CNBC's Meg Tirrell talks about whether the FDA will approve Sarepta's Muscular Dystrophy drug and what could happen to the company's stock. The "FMHR" traders debate the trade.

  • Elizabeth Holmes, founder and CEO of Theranos.

    Blood-testing startup Theranos posted a job opening Thursday looking for an executive assistant to CEO Elizabeth Holmes.

  • Targeting cancer

    Robert Mulroy, Merrimack Pharmaceuticals CEO, discusses the company's oncology pipeline and clinical basket trial.

  • Heart attack gene?

    Amgen is working on a drug to lower the risk of heart attack, reports CNBC's Meg Tirrell.

  • Russian tennis chief says Maria Sharapova may never play again

    The tennis star tested positive for a banned drug at the Australian Open in January.

  • NEW YORK, May 19- Health insurer Cigna Corp plans to cut its customers' prescriptions for opioid treatments by 25 percent over the next three years, putting its weight behind a U.S. government battle against addictive painkillers. President Barack Obama earlier this year asked Congress for $1.1 billion in new funding over two years to expand treatment for a...

  • BOGOTA, Colombia— Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals. Memos leaked last week to a nonprofit group, written from the Colombian Embassy in Washington, describe intense lobbying...

  • DOJ opens investigation into Russian doping scandal -NYT

    CNBC's Eamon Javers reports on the Department of Justice opening an investigation into the Russian doping scandal, according to the New York Times.

  • May 17- Walgreens Boots Alliance Inc. is making the opioid antidote naloxone available without a prescription in all its pharmacies in New Mexico, part of a plan to make the drug readily available in 35 states by the end of this year. The drugstore chain has already made naloxone available without a prescription in Alabama, Indiana, Massachusetts, New Jersey, New...

  • Citron to Mallinckrodt: Test your drug!

    Citron Research's executive editor Andrew Left is long Valeant, short Mallinckrodt Pharmaceuticals.

  • Biggest seizure of drugs in history

    More than eight tons of cocaine were seized in Colombia, reports CNBC's Michelle Caruso-Cabrera.

  • Pfizer blocks use of its drugs in executions: NYT

    CNBC's Sue Herera provides insight to a report regarding drugs used in lethal injections.

  • Falls upends

    Shares of Valeant fell nearly 6 percent after the New York Times reported the company has not kept the discount promises it made to Congress.

  • Valeant: Broken promises?

    CNBC's Meg Tirrell reports on Valeant possibly not living up to its promise to offer discounts on some drugs.

  • Analyst on Valeant: Scrutiny will only get worse

    David Amsellem of Piper Jaffray discusses a report that hospitals are still waiting on Valeant's promised drug discounts.